AD/PD 2026: Biomarker Counseling and Disclosure in MCI and SCD

In this MEDtalk from the AD/PD 2026 Conference, Marie Bruun, MD, PhD, Researcher at the Danish Dementia Research Centre, presents preliminary results on biomarker counseling and diagnostic disclosure in individuals with mild cognitive impairment (MCI) and subjective cognitive decline (SCD). Participants emphasized understanding personal AD risk, treatment, and risk reduction, and valued opportunities to ask questions. Visual aids or recorded consultations were preferred, and most felt well informed with no regrets about receiving their diagnosis.